afami-cel,adp-a2m4cd8,nivolumab
daptimmune,bms
['surpass', 'ovarian', 'a2m4cd8', 'gastroesophageal', 'adp-a2m4', 'esophageal']
 emerging data signals encouraging clinical outcomes, especially for gastroesophageal and ovarian cancers for which 2 phase 2 trials have been or will be initiated, dr. david hong on the surpass trial of adp-a2m4cd8. #esmo22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.